Vir Biotechnology to Unveil Expanded Phase 2 Data for Hepatitis…

Event summary

Vir Biotechnology will present expanded Phase 2 SOLSTICE trial results for elebsiran and tobevibart in hepatitis delta at AASLD’s The Liver Meeting® 2026 on November 8, 2026.
Two oral presentations scheduled: one on efficacy patterns through Week 96 and another on intrahepatic NK cell remodeling.
Elebsiran (siRNA) and tobevibart (monoclonal antibody) are investigational agents designed to disrupt the hepatitis delta virus life cycle.
Chronic hepatitis delta is the most severe form of chronic viral hepatitis, with limited approved treatments currently available.

The big picture

Vir Biotechnology’s presentation of expanded Phase 2 data for its hepatitis delta combination therapy comes at a critical juncture, as chronic hepatitis delta remains a severe and underserved condition with limited treatment options. The company’s approach of targeting multiple points in the virus life cycle could position it as a leader in this space, provided the data supports further development. The broader biotech industry is watching closely, as successful outcomes could validate the combination therapy model for other infectious diseases.

What we're watching

Clinical Efficacy: Whether the combination therapy achieves undetectable HDV RNA levels, a critical marker for improved clinical outcomes in chronic hepatitis delta.
Regulatory Pathway: The pace at which Vir Biotechnology can advance to Phase 3 trials and potential regulatory approvals based on these results.
Market Differentiation: How the efficacy and safety profile of elebsiran and tobevibart compare to existing and emerging treatments for chronic hepatitis delta.